152 related articles for article (PubMed ID: 37877262)
1. Pharmacokinetic correlation of structurally modified chalcone derivatives as promising leads to treat tuberculosis.
Sabarathinam S; Ganamurali N; Satheesh S; Dhanasekaran D; Raja A
Future Med Chem; 2023 Oct; 15(20):1903-1913. PubMed ID: 37877262
[TBL] [Abstract][Full Text] [Related]
2. The Medicinal Chemistry of Chalcones as Anti-
Rodríguez-Silva CN; Prokopczyk IM; Dos Santos JL
Mini Rev Med Chem; 2022; 22(16):2068-2080. PubMed ID: 35156577
[TBL] [Abstract][Full Text] [Related]
3. Chalcones and flavonoids as anti-tuberculosis agents.
Lin YM; Zhou Y; Flavin MT; Zhou LM; Nie W; Chen FC
Bioorg Med Chem; 2002 Aug; 10(8):2795-802. PubMed ID: 12057669
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of novel furan-based chalcone derivatives as anti-tuberculosis agents:
Dhivya LS; Kumaradoss KM
Future Med Chem; 2023 Sep; 15(18):1687-1701. PubMed ID: 37732414
[No Abstract] [Full Text] [Related]
5. Novel aryloxy azolyl chalcones with potent activity against Mycobacterium tuberculosis H37Rv.
Marrapu VK; Chaturvedi V; Singh S; Singh S; Sinha S; Bhandari K
Eur J Med Chem; 2011 Sep; 46(9):4302-10. PubMed ID: 21764184
[TBL] [Abstract][Full Text] [Related]
6. Current prospects of synthetic curcumin analogs and chalcone derivatives against mycobacterium tuberculosis.
Bukhari SN; Franzblau SG; Jantan I; Jasamai M
Med Chem; 2013 Nov; 9(7):897-903. PubMed ID: 23305394
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3-Triazoles: A Computational Docking Techniques.
Sadineni K; Reddy Basireddy S; Rao Allaka T; Yatam S; Bhoomandla S; Muvvala V; Babu Haridasyam S
Chem Biodivers; 2024 May; 21(5):e202400389. PubMed ID: 38457745
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anti-Tb evaluation of chalcone derivatives as novel inhibitors of InhA.
L S D; M K K; Thamilselvan G
J Biomol Struct Dyn; 2023; 41(24):15165-15176. PubMed ID: 37349907
[TBL] [Abstract][Full Text] [Related]
9. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
10. Antimycobacterial and anti-inflammatory activities of substituted chalcones focusing on an anti-tuberculosis dual treatment approach.
Ventura TL; Calixto SD; de Azevedo Abrahim-Vieira B; de Souza AM; Mello MV; Rodrigues CR; Soter de Mariz e Miranda L; Alves de Souza RO; Leal IC; Lasunskaia EB; Muzitano MF
Molecules; 2015 May; 20(5):8072-93. PubMed ID: 25951004
[TBL] [Abstract][Full Text] [Related]
11. Chalcone Derivatives: Role in Anticancer Therapy.
Ouyang Y; Li J; Chen X; Fu X; Sun S; Wu Q
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208562
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and
Dhivya LS; Pradeepa BR; Sarvesh S
Future Med Chem; 2022 Jun; 14(12):851-866. PubMed ID: 35548879
[No Abstract] [Full Text] [Related]
13. Pyrazole-coumarin and pyrazole-quinoline chalcones as potential antitubercular agents.
Kumar G; Siva Krishna V; Sriram D; Jachak SM
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000077. PubMed ID: 32484273
[TBL] [Abstract][Full Text] [Related]
14. Syntheses of lipophilic chalcones and their conformationally restricted analogues as antitubercular agents.
Ahmad I; Thakur JP; Chanda D; Saikia D; Khan F; Dixit S; Kumar A; Konwar R; Negi AS; Gupta A
Bioorg Med Chem Lett; 2013 Mar; 23(5):1322-5. PubMed ID: 23369537
[TBL] [Abstract][Full Text] [Related]
15. Design, Facile Synthesis and Characterization of Dichloro Substituted Chalcones and Dihydropyrazole Derivatives for Their Antifungal, Antitubercular and Antiproliferative Activities.
Shaik AB; Bhandare RR; Nissankararao S; Edis Z; Tangirala NR; Shahanaaz S; Rahman MM
Molecules; 2020 Jul; 25(14):. PubMed ID: 32668655
[TBL] [Abstract][Full Text] [Related]
16. Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach.
Rathod S; Chavan P; Mahuli D; Rochlani S; Shinde S; Pawar S; Choudhari P; Dhavale R; Mudalkar P; Tamboli F
J Mol Model; 2023 Mar; 29(4):113. PubMed ID: 36971900
[TBL] [Abstract][Full Text] [Related]
17. New chalcone-sulfonamide hybrids exhibiting anticancer and antituberculosis activity.
Castaño LF; Cuartas V; Bernal A; Insuasty A; Guzman J; Vidal O; Rubio V; Puerto G; Lukáč P; Vimberg V; Balíková-Novtoná G; Vannucci L; Janata J; Quiroga J; Abonia R; Nogueras M; Cobo J; Insuasty B
Eur J Med Chem; 2019 Aug; 176():50-60. PubMed ID: 31096118
[TBL] [Abstract][Full Text] [Related]
18. DFT-based QSAR models to predict the antimycobacterial activity of chalcones.
Barua N; Sarmah P; Hussain I; Deka RC; Buragohain AK
Chem Biol Drug Des; 2012 Apr; 79(4):553-9. PubMed ID: 22151277
[TBL] [Abstract][Full Text] [Related]
19. Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis.
Muradás TC; Abbadi BL; Villela AD; Macchi FS; Bergo PF; de Freitas TF; Sperotto NDM; Timmers LFSM; Norberto de Souza O; Picada JN; Fachini J; da Silva JB; de Albuquerque NCP; Habenschus MD; Carrão DB; Rocha BA; Barbosa Junior F; de Oliveira ARM; Mascarello A; Neuenfeldf P; Nunes RJ; Morbidoni HR; Campos MM; Basso LA; Rodrigues-Junior VS
PLoS One; 2018; 13(8):e0202568. PubMed ID: 30114296
[TBL] [Abstract][Full Text] [Related]
20. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
